119 related articles for article (PubMed ID: 37941520)
21. Deciphering the Molecular Mechanism of Spontaneous Senescence in Primary Epithelial Ovarian Cancer Cells.
Pakuła M; Mały E; Uruski P; Witucka A; Bogucka M; Jaroszewska N; Makowska N; Niklas A; Moszyński R; Sajdak S; Tykarski A; Mikuła-Pietrasik J; Książek K
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012719
[TBL] [Abstract][Full Text] [Related]
22. Characteristics and growth patterns of human peritoneal mesothelial cells: comparison between advanced epithelial ovarian cancer and non-ovarian cancer sources.
Zhang XY; Pettengell R; Nasiri N; Kalia V; Dalgleish AG; Barton DP
J Soc Gynecol Investig; 1999; 6(6):333-40. PubMed ID: 10643588
[TBL] [Abstract][Full Text] [Related]
23. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
24. Identification of a pyridine derivative inducing senescence in ovarian cancer cell lines via P21 activation.
Shang D; Wu Y; Ding Y; Lu Z; Shen Y; Zhu F; Liu H; Zhu C; Tu Z
Clin Exp Pharmacol Physiol; 2018 May; 45(5):452-460. PubMed ID: 29143360
[TBL] [Abstract][Full Text] [Related]
25. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
Faria RS; de Lima LI; Bonadio RS; Longo JPF; Roque MC; de Matos Neto JN; Moya SE; de Oliveira MC; Azevedo RB
Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249
[TBL] [Abstract][Full Text] [Related]
26. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
27. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.
Syed N; Coley HM; Sehouli J; Koensgen D; Mustea A; Szlosarek P; McNeish I; Blagden SP; Schmid P; Lovell DP; Hatzimichael E; Crook T
Cancer Res; 2011 May; 71(9):3317-27. PubMed ID: 21402713
[TBL] [Abstract][Full Text] [Related]
28. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
Wang H; Zhu L; Gao J; Hu Z; Lin B
Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
[TBL] [Abstract][Full Text] [Related]
29. Procancerogenic activity of senescent cells: A case of the peritoneal mesothelium.
Mikuła-Pietrasik J; Stryczyński Ł; Uruski P; Tykarski A; Książek K
Ageing Res Rev; 2018 May; 43():1-9. PubMed ID: 29355719
[TBL] [Abstract][Full Text] [Related]
30. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence.
Bitler BG; Nicodemus JP; Li H; Cai Q; Wu H; Hua X; Li T; Birrer MJ; Godwin AK; Cairns P; Zhang R
Cancer Res; 2011 Oct; 71(19):6184-94. PubMed ID: 21816908
[TBL] [Abstract][Full Text] [Related]
31. Senescent peritoneal mesothelial cells promote ovarian cancer cell adhesion: the role of oxidative stress-induced fibronectin.
Ksiazek K; Mikula-Pietrasik J; Korybalska K; Dworacki G; Jörres A; Witowski J
Am J Pathol; 2009 Apr; 174(4):1230-40. PubMed ID: 19246646
[TBL] [Abstract][Full Text] [Related]
32. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.
Lu H; Liu Y; Wang D; Wang L; Zhou H; Xu G; Xie L; Wu M; Lin Z; Yu Y; Li G
Tumour Biol; 2016 Aug; 37(8):11469-77. PubMed ID: 27012551
[TBL] [Abstract][Full Text] [Related]
33. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
[TBL] [Abstract][Full Text] [Related]
34. Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
Scalici JM; Arapovic S; Saks EJ; Atkins KA; Petroni G; Duska LR; Slack-Davis JK
Cancer; 2017 May; 123(6):977-984. PubMed ID: 28263384
[TBL] [Abstract][Full Text] [Related]
35. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
36. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Schwandt A; von Gruenigen VE; Wenham RM; Frasure H; Eaton S; Fusco N; Fu P; Wright JJ; Dowlati A; Waggoner S
Invest New Drugs; 2014 Aug; 32(4):729-38. PubMed ID: 24619298
[TBL] [Abstract][Full Text] [Related]
38. Irinotecan induces senescence and apoptosis in colonic cells in vitro.
Rudolf E; John S; Cervinka M
Toxicol Lett; 2012 Oct; 214(1):1-8. PubMed ID: 22898888
[TBL] [Abstract][Full Text] [Related]
39. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ;
Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365
[TBL] [Abstract][Full Text] [Related]
40. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
Weigel MT; Rath K; Alkatout I; Wenners AS; Schem C; Maass N; Jonat W; Mundhenke C
Oncology; 2014; 87(4):232-45. PubMed ID: 25116401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
